The publication reviews the results of 204 patients with 12 tumor types enrolled and treated on the eNRGy study, concluding “Zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ ...

Others include a partnership between Biogen and Sangamo and Eli Lilly's $1 billion takeover of Prevail in 2020 ... drug developers including Gain Therapeutics, MODAG, and Alterity Therapeutics.

For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover, develop and deliver innovative medicines that help patients prevail ... which was a cancer therapeutics company ...

EAU CLAIRE, Wis. (WEAU) - A car crashed into Prevail Bank on Fairfax Street by HyVee Friday evening. Our photojournalist on scene saw the car almost completely in the building with a tow truck pulling ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Dividend stocks can be terrific investments. The best ones provide investors with passive income and upside potential. Over ...

Greetings. Welcome to Leidos fourth-quarter fiscal year 2024 earnings call. (Operator Instructions) Please note, this conference is being recorded. At this time, I will turn the conference over to ...

MANILA, Philippines — The shear line and the northeast monsoon will continue to bring cloudy skies and rains to several areas of the country, the weather bureau said Saturday. In its 4 a.m. bulletin, ...

Suntory boss expects to sell less in Europe, Canada and Mexico as a result of US president’s protectionist trade policies ...

Good day, and thank you for standing by. Welcome to the Arm third quarter fiscal year 2025 webcast and conference call. At this time, all participants are in a listen-only mode. After the speakers ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

Bristol Myers Squibb today reports results for the fourth quarter and full year of 2024. "We made good progress in 2024, which was capped by a fourth quarter of strong topline growth driven by key ...